No Upper Age Limit for Ofev (Nintedanib)
There is no upper age limit for Ofev (nintedanib) treatment. The FDA label explicitly states that the drug has been studied and used safely in patients up to 87 years of age, with no restrictions based on age alone 1.
Evidence from Clinical Trials and FDA Labeling
The FDA drug label provides clear data on elderly patients:
- In IPF trials: 61% of patients were ≥65 years old, and 16% were ≥75 years old 1
- In progressive fibrosing ILD trials: 61% were ≥65 years old, and 19% were ≥75 years old, with patients ranging from 27 to 87 years 1
- In SSc-ILD trials: 21.4% were ≥65 years old, with patients ranging from 20 to 79 years 1
The FDA label explicitly states: "no overall differences in effectiveness were observed between subjects who were 65 and over and younger subjects; no overall differences in safety were observed between subjects who were 65 and over or 75 and over and younger subjects" 1.
Real-World Evidence in Very Elderly Patients
Recent high-quality research confirms safety and efficacy in the oldest patients:
A 2023 multicenter Italian study specifically evaluated patients >80 years old and found nintedanib equally effective and safe compared to younger patients, with no significant differences in FVC decline, adverse events, hospitalizations, or mortality 2
A 2026 Japanese multicenter study of patients ≥75 years demonstrated comparable efficacy in attenuating FVC decline and similar safety profiles, though older patients had shorter survival due to diminished physiological reserve rather than drug-related issues 3
Clinical Implications
Age alone should never be a barrier to prescribing nintedanib. The decision should be based on:
- Hepatic function: Dose reduction to 100 mg BID required for Child-Pugh A; contraindicated in Child-Pugh B or C 1
- Renal function: No adjustment needed for mild-moderate impairment; not studied in severe impairment (<30 mL/min CrCl) 1
- Tolerability monitoring: Elderly patients may require dose adjustments for gastrointestinal side effects, but discontinuation rates are comparable to younger patients 2, 3
The evidence consistently demonstrates that very elderly patients (including those >80 years) derive similar benefit from nintedanib as younger patients, with manageable side effects 2, 3.